噻托溴铵吸入剂对合并慢阻肺的良性前列腺增生患者排尿障碍的影响

发布时间：2018-05-17 07:32

  本文选题：肺疾病慢性阻塞性 + 噻托溴铵　； 参考：《实用医学杂志》2017年03期

【摘要】：目的:研究噻托溴铵吸入剂对合并慢阻肺的良性前列腺增生患者排尿障碍的影响。方法:前瞻性研究96例使用噻托溴铵吸入剂治疗合并慢阻肺的良性前列腺增生患者为治疗组,设25例未吸入制剂的患者为对照组,治疗6个月后采用国际前列腺症状评分表(IPSS)、生活质量量表(QOL)、最大尿流率(Q_(Max))、平均尿流率(Q_(ave))、达最大尿流率时间(TTQ_(Max))、残余尿量(PVR)、膀胱排尿效率(BVE%)对患者进行排尿障碍评价,所有患者均检查肺功能、前列腺体积、前列腺特异性抗原(PSA)水平。结果:噻托溴铵吸入剂治疗前、治疗6个月和对照组比较,IPSS(15.1±4.1、16.3±3.4和14.7±3.1,P=0.864);QOL(3.9±0.8、4.0±0.8和4.0±0.9,P=0.992);Q_(Max)(ml/s)(8.5±2.9、10.9±2.2和9.0±2.4,P=0.214);Qave(ml/s)(3.9±1.2、5.0±1.4和3.8±0.9,P=0.054);TTQ_(Max)(s)(11.1±5.6、11.2±4.0和10.4±5.1,P=0.424);PVR(mL)(56.8±33.3、62.3±30.5和57.4±29.5,P=0.981);BVE(%)(75.6±13.8、72.7±10.5和74.3±12.1,P=0.992),以上均差异无统计学意义。结论:噻托溴铵吸入剂不引起合并慢阻肺的良性前列腺增生患者发生排尿障碍。
[Abstract]:Aim: to study the effect of tiotropium bromide inhalation on dysuria in patients with benign prostatic hyperplasia (BPH) complicated with chronic obstructive pulmonary disease (COPD). Methods: in a prospective study, 96 patients with benign prostatic hyperplasia with chronic obstructive pulmonary disease were treated with tiotropium bromide inhalation as the treatment group, and 25 patients without inhaled preparations as the control group. After 6 months of treatment, the patients were evaluated with IPSS scale, quality of life scale (QOLL), maximum urinary flow rate (MVF), QV Maxtix, average uroflow rate (UF), maximum urinary flow time (TTV), residual urine volume (PVR) and bladder urination efficiency (BVEI). All patients were examined for lung function, prostate volume and prostate specific antigen (PSA) level. 缁撴灉:鍣绘墭婧撮摰鍚稿叆鍓傛不鐤楀墠,娌荤枟6涓�鏈堝拰瀵圭収缁勬瘮杈�,IPSS(15.1卤4.1,16.3卤3.4鍜，

本文编号：1900525